Autolus Therapeutics plc
AUTL
$1.59
$0.117.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -10.99% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -10.99% | -- | -- |
| Cost of Revenue | 40.21% | 2,378.34% | 45.69% | 17.87% | 2,544.13% |
| Gross Profit | 12.36% | -381.87% | -73.48% | -17.85% | -3,503.49% |
| SG&A Expenses | 32.75% | 38.18% | 62.48% | 77.77% | 157.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.19% | 40.37% | 51.94% | 42.47% | 57.59% |
| Operating Income | -5.87% | -4.62% | -68.32% | -42.41% | -59.10% |
| Income Before Tax | 4.25% | 18.38% | -28.92% | 66.13% | -78.92% |
| Income Tax Expenses | 2,318.18% | 678.43% | 27,912.50% | 6,191.67% | 204.76% |
| Earnings from Continuing Operations | 3.63% | 17.77% | -33.16% | 64.23% | -79.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.63% | 17.77% | -33.16% | 64.23% | -79.05% |
| EBIT | -5.87% | -4.62% | -68.32% | -42.41% | -59.10% |
| EBITDA | -5.13% | -3.94% | -70.39% | -43.29% | -59.72% |
| EPS Basic | 3.63% | 17.81% | -11.13% | 76.61% | -17.08% |
| Normalized Basic EPS | 4.06% | 17.82% | -7.62% | 77.95% | -17.69% |
| EPS Diluted | 3.63% | 17.81% | -11.13% | 76.61% | -17.08% |
| Normalized Diluted EPS | 4.06% | 17.82% | -7.62% | 77.95% | -17.69% |
| Average Basic Shares Outstanding | 0.02% | 0.04% | 19.78% | 52.91% | 52.94% |
| Average Diluted Shares Outstanding | 0.02% | 0.04% | 19.78% | 52.91% | 52.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |